未登录

A

Alexandre Vivot

assistance publique hopitaux paris (aphp)

H指数:16

被引数:1,069

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comment on: Application of a new serratus anterior plane block in modified radical mastectomy under ultrasound guidance: A prospective, randomized controlled trial

JOURNAL OF CLINICAL ANESTHESIA

IF5.1

2021-12-010

PREAI

Impact of oxygen tension according to embryo stage of development: a prospective randomized study

SCIENTIFIC REPORTS

IF3.9

2021-11-1614

OAAI

Bayesian analysis from phase III trials was underused and poorly reported: a systematic review

JOURNAL OF CLINICAL EPIDEMIOLOGY

IF5.2

2020-07-015

OAAI

Application of Basic Epidemiologic Principles and Electronic Health Records in a Deep Learning Prediction Model

JAMA DERMATOLOGY

IF11

2020-04-013

PREAI

A Methodologic Systematic Review of Mobile Health Behavior Change Randomized Trials

AMERICAN JOURNAL OF PREVENTIVE MEDICINE

IF4.5

2019-12-019

OAAI

Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study

EUROPEAN RESPIRATORY JOURNAL

IF21

2019-11-210

PRE

Living network meta-analysis was feasible when considering the pace of evidence generation

JOURNAL OF CLINICAL EPIDEMIOLOGY

IF5.2

2019-04-0114

PREAI

Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2019-01-048

OAAI

Impact of Biomarker-based Design Strategies on the Risk of False-Positive Findings in Targeted Therapy Evaluation

CLINICAL CANCER RESEARCH

IF10.2

2018-12-132

OAAI

Benefit of immune checkpoint inhibitors (ICIs) for second-line treatment of advanced non-small cell lung cancer (NSCLC) using restricted mean survival time (RMST).

EUROPEAN RESPIRATORY JOURNAL

IF21

2018-11-190

PRE

Mapping of Crowdsourcing in Health: Systematic Review

健康众包的映射: 系统综述

JOURNAL OF MEDICAL INTERNET RESEARCH

IF6

2018-05-1596

OAAI

Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis

2005至2010间FDA和EMA批准的新药上市后研究的相关因素: 多变量分析

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2018-02-244

PREAI

Should we consider day-2 and day-3 embryo morphology before day-5 transfer when blastocysts reach a similar good quality?

REPRODUCTIVE BIOMEDICINE ONLINE

IF3.5

2017-11-0132

OAAI

Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2017-10-1213

OAAI

Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing

FDA批准的具有所需药物基因组生物标志物测试的肿瘤药物的治疗与生物标志物相互作用的证据

SCIENTIFIC REPORTS

IF3.9

2017-07-3123

OAAI

Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015

ANNALS OF ONCOLOGY

IF65.4

2017-05-0197

OAAI

Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov

GENETICS IN MEDICINE

IF6.2

2016-08-017

OAAI

Jump, Hop, or Skip: Modeling Practice Effects in Studies of Determinants of Cognitive Change in Older Adults

AMERICAN JOURNAL OF EPIDEMIOLOGY

IF4.8

2016-01-2889

OAAI

Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs

GENETICS IN MEDICINE

IF6.2

2015-09-0137

OAAI

Association of Alzheimer's related genotypes with cognitive decline in multiple domains: results from the Three-City Dijon study

MOLECULAR PSYCHIATRY

IF10.1

2015-06-0234

OAAI